Literature DB >> 8453966

The relation between type of renal disease and renal drug clearance in children.

C M Paap1, M C Nahata.   

Abstract

It is generally assumed that the renal clearance of drugs in patients with renal impairment are affected to a similar extent regardless of the type of renal disease (intact nephron hypothesis). We have studied the effect of underlying renal disease on the pharmacokinetics of cefotaxime and desacetylcefotaxime in two groups of children (ages 7 to 16 y) with varying degrees of renal dysfunction. Patients in group 1 (n = 5) had intrinsic renal disease and those in group 2 (n = 5) had extrinsic renal disease, as identified by the primary renal lesion. After a single intravenous dose of cefotaxime timed blood and urine samples were collected for 24 h; cefotaxime and desacetylcefotaxime were measured by HPLC. There were no significant differences between the groups in age, body surface area, urine output, creatinine clearance, total body clearance, nonrenal clearance, renal clearance, and volume of distribution at steady state of cefotaxime, and renal clearance of desacetylcefotaxime. However, the renal clearance: creatinine clearance (CLR:CLCR) ratios for both cefotaxime [1.34 in group 1 vs. 0.51 in group 2] and desacetylcefotaxime [1.58 in group 1 vs. 0.75 in group 2] were statistically significant between the two groups. Group 1 patients had an average CLR:CLCR ratio greater than 1 for both the parent compound and the metabolite, suggesting that net tubular secretion was still intact, despite a diminished glomerular filtration rate (CLCR = 24 ml.min-1.73 m-2).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453966     DOI: 10.1007/bf00315480

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis.

Authors:  D W Bourne
Journal:  Comput Methods Programs Biomed       Date:  1989-07       Impact factor: 5.428

2.  Ampicillin and cephalexin in renal insufficiency.

Authors:  R Hori; K Okumura; A Kamiya; H Nihira; H Nakano
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

3.  Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.

Authors:  C M Paap; M C Nahata; M A Mentser; J D Mahan; S K Puri; J W Hubbard
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

4.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  Moment analysis of drug disposition in kidney. III: Transport of p-aminohippurate and tetraethylammonium in the perfused kidney isolated from uranyl nitrate-induced acute renal failure rats.

Authors:  Y Tanigawara; Y Saito; T Aiba; K Ohoka; A Kamiya; R Hori
Journal:  J Pharm Sci       Date:  1990-03       Impact factor: 3.534

6.  A new dosing regimen in renal insufficiency: application to cephalexin.

Authors:  R Hori; K Okumura; H Nihira; H Nakano; K Akagi; A Kamiya
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

7.  Differential effects of the degree of renal damage on p-aminohippuric acid and inulin clearances in rats.

Authors:  C A Gloff; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-04
  7 in total
  1 in total

1.  Pharmacokinetics of quinine in patients with chronic renal failure.

Authors:  P Rimchala; J Karbwang; K Sukontason; V Banmairuroi; P Molunto; K Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.